Research Grant
[Cite as https://purl.org/au-research/grants/nhmrc/570952]Researchers: Prof Des Richardson (Principal investigator) , Dr Danuta Kalinowski , Dr David Lovejoy , Prof Paul Bernhardt
Brief description Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
Funding Amount $AUD 585,455.79
Funding Scheme NHMRC Project Grants
Notes Standard Project Grant
- nhmrc : 570952
- PURL : https://purl.org/au-research/grants/nhmrc/570952
